INP20 for peanut hypersensitivity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Nov 2019: Trial registered, NCT04163562
  2. 11 Mar 2020: Trial started, NCT04163562

The trials

NCT04163562: Oral Immunotherapy for Peanut Allergic Patients

State
Under way
Phase
Phase 1 and Phase 2
People
50 planned
Started
11 Mar 2020
Primary completion
May 2025
Arms
INP20 (Oral Immunotherapy)
Results
None posted
  1. 14 Nov 2019: Trial registered
  2. 11 Mar 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.